Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Johnson & Johnson (NYSE:JNJ) had its target price upped by investment analysts at Rothschild & Co Redburn from $180.00 to $210.00 in a report released on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the stock. Rothschild & Co Redburn’s price target suggests a potential downside of 14.40% from the company’s previous close.

Several other equities research analysts have also recently issued reports on JNJ. Freedom Capital cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. HSBC raised their target price on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Finally, Bank of America boosted their price target on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $232.70.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $1.59 during midday trading on Thursday, reaching $245.32. 952,842 shares of the company’s stock traded hands, compared to its average volume of 9,161,753. The company has a fifty day simple moving average of $220.45 and a two-hundred day simple moving average of $198.55. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.96. The company has a market cap of $591.20 billion, a P/E ratio of 22.20, a PEG ratio of 2.38 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of JNJ. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. State Street Corp boosted its position in Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after purchasing an additional 1,663,782 shares in the last quarter. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $6,924,523,000. Finally, Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after buying an additional 956,239 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company is preparing a potential sale of its orthopedics unit that could fetch about $20 billion — investors may view a sale as value‑unlocking and a catalyst for multiple expansion if executed. Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports
• Positive Sentiment: Announced a >$1 billion investment in a Pennsylvania cell‑therapy manufacturing facility — expands U.S. capacity for high‑value biologics/cell therapies and supports long‑term revenue pipeline potential. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: Strong early oncology data: investigational RYBREVANT FASPRO plus immunotherapy showed a 56% overall response rate in frontline recurrent/metastatic head & neck cancer — clinical upside that could boost future drug sales if confirmed. RYBREVANT FASPRO clinical results PR
• Positive Sentiment: Dividend/return focus highlighted in recent roundups — J&J remains a reliable dividend payer (recent quarterly payout noted), supporting income investor demand. Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
• Neutral Sentiment: Options and analyst attention have increased — can amplify near‑term moves but are not fundamental drivers by themselves. Monitor for large directional trades or fresh analyst revisions. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street coverage (Zacks, TipRanks) is keeping JNJ in focus — useful for sentiment but incremental to fundamental changes. Johnson & Johnson (JNJ) Is a Trending Stock
• Negative Sentiment: Insider selling: recent filings show EVP sales totaling millions of dollars (several thousand shares at ~$243–$244), which can be read negatively by some investors even if sales have benign explanations. Johnson & Johnson EVP Vanessa Broadhurst Sells 6,197 Shares
• Negative Sentiment: Ongoing talc litigation and renewed media focus on verdict risk continue to cloud valuation — legal overhang can limit multiple expansion and keeps headline risk elevated. Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.